Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Receivables (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed Receivables for 13 consecutive years, with $7.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables rose 0.97% to $7.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.3 million, a 0.97% increase, with the full-year FY2025 number at $7.3 million, up 0.97% from a year prior.
  • Receivables was $7.3 million for Q4 2025 at Ekso Bionics Holdings, up from $6.0 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $7.3 million in Q4 2025 to a low of $2.3 million in Q1 2021.
  • A 5-year average of $5.1 million and a median of $4.9 million in 2023 define the central range for Receivables.
  • Peak YoY movement for Receivables: soared 72.84% in 2023, then crashed 30.48% in 2025.
  • Ekso Bionics Holdings' Receivables stood at $4.7 million in 2021, then fell by 0.79% to $4.6 million in 2022, then increased by 22.05% to $5.6 million in 2023, then increased by 28.22% to $7.2 million in 2024, then increased by 0.97% to $7.3 million in 2025.
  • Per Business Quant, the three most recent readings for EKSO's Receivables are $7.3 million (Q4 2025), $6.0 million (Q3 2025), and $4.5 million (Q2 2025).